Ticker

Analyst Price Targets — CMS

Page 1 • Showing up to 10
DateAnalystFirmTargetPrice @ PostSourceHeadline
July 16, 2026 9:46 amJefferies$78.00$74.03StreetInsider CMS Energy (CMS) PT Raised to $78 at JefferiesMember Login
July 14, 2026 9:40 amBarclays$81.00$75.75TheFly CMS Energy price target raised to $81 from $79 at Barclays
June 8, 2026 12:52 pmSophie KarpKeyBanc$83.00$71.31StreetInsider KeyBanc Reiterates Overweight Rating on CMS Energy (CMS) Following CFO Transition
June 4, 2026 11:40 amJames ThalackerBMO Capital$81.00$70.22TheFly CMS Energy price target lowered to $81 from $82 at BMO Capital
June 4, 2026 8:45 amJulien Dumoulin-SmithJefferies$74.00$70.22TheFly CMS Energy downgraded to Hold from Buy at Jefferies
May 21, 2026 2:44 pmMorgan Stanley$77.00$73.46TheFly CMS Energy price target lowered to $77 from $81 at Morgan Stanley
May 18, 2026 11:21 amTruist Financial$83.00$71.64TheFly CMS Energy price target lowered to $83 from $86 at Truist
May 11, 2026 12:00 pmBMO Capital$82.00$72.97TheFly CMS Energy price target lowered to $82 from $85 at BMO Capital
April 21, 2026 10:39 amWells Fargo$80.00$77.04TheFly CMS Energy price target raised to $80 from $74 at Wells Fargo
April 17, 2026 11:34 amBMO Capital$85.00$78.11TheFly CMS Energy price target lowered to $85 from $86 at BMO Capital

Latest News for CMS

Plug This 3% Yield In, Light Up Your Portfolio's Returns: CMS Energy

CMS Energy (CMS) is reaffirmed as a Buy, supported by a $24 billion five-year capex plan driving robust rate base and EPS growth. CMS targets 6–8% annual adjusted EPS growth, with consensus estimates at the high end, and maintains a stable BBB credit rating. Shares trade at a modest 3% discount to fair value, with potential for 9%+ annual total returns through 2031, underpinned by disciplined capital deployment.

Seeking Alpha • Jul 14, 2026
Deepening Collaboration in AI-Powered R&D Acceleration: Insilico Medicine and CMS announce additional collaborations in CNS diseases

SHANGHAI, July 12, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 03696.HK), a clinical-stage biotechnology company driven by generative artificial intelligence (AI), and China Medical System Holdings Limited ("CMS", 867.HK/8A8.SG), an open-platform innovative company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, today announced an additional…

PRNewsWire • Jul 12, 2026

🧮 Earnings Move Analyzer

Insider Trading

Insider Trading

NameRoleDateTypeSharesPriceFormLink

Senate Trading Disclosures

NameTransaction DateTypeAssetAmountLink

House Trades Disclosures

NameTransaction DateTypeAssetAmountLink

Options Chain

Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.

Scroll to Top